About HBM HOLDINGS-B Company

We are a clinical-stage biopharmaceutical company incorporated in July 2016 to research and develop differentiated antibody therapies in the fields of tumor immunity and autoimmune diseases. We are committed to the discovery, development, and commercialization of innovative antibody therapies to meet unmet patient needs. In 2022, we established two sub-brands, Harbour Therapeutics focused on pipeline development, product collaboration and commercialization, and Nona Biosciences, a biotech company providing total solutions to global partners. Rich product portfolio and differentiated pipeline At Harbour Therapeutics, we have a rich and differentiated product pipeline with more than ten potential drug candidates, of which HBM9161, HBM4003, and HBM7008 are our main products. bartolizumab (HBM9161) Bartolizumab is an all-human monoclonal antibody that selectively binds to and inhibits neonatal crystal fragment receptors (“FcRn”). FcRn plays a key role in preventing IgG antibody degradation. High levels of pathogenic IgG antibodies induce a variety of autoimmune diseases. As the most clinically advanced Fc Rn inhibitor developed in Greater China, bartolizumab has the potential to become a breakthrough treatment for many types of autoimmune diseases in Greater China. On October 10, 2022, we reached a licensing agreement with CSPC Enbipu Pharmaceutical Co., Ltd. (Enbipu Pharmaceutical, a wholly-owned subsidiary of CSPC Pharmaceutical Holding Group Co., Ltd.). According to the agreement, we will grant EnbiPu Pharmaceutical an exclusive, transferable technical license to develop, produce and commercialize the authorized product batoclimab (referring to any drug or biological product containing batoclimab) in the Greater China region (including Hong Kong, Macau and Taiwan). HBM4003 HBM4003 is a new generation all-human anti-CTLA-4 antibody that can be used to inhibit T-lymphocyte-associated antigen-4 (CTLA-4), one of the major negative cytotoxic factors regulating T-cell response. It is also the first internally developed molecule produced through our HCaB platform, and has progressed from drug candidate screening to clinical within three years. HBM4003 is the world's first all-human heavy chain antibody to enter clinical development, and in the pre-clinical stage, it has good characteristics compared to traditional anti-CTLA-4 antibodies. Compared to conventional anti-CTLA-4 antibodies, HBM4003 has significantly increased T-regulatory cell elimination mechanism and improved pharmacokinetics (“PK”) characteristics. At the same time, by enhancing the antibody-dependent cytotoxicity (“ADCC”) strategy to enhance HBM4003's selective Treg cell elimination potential, we believe HBM4003 will be able to break the immunosuppressive barrier of anti-tumor immunotherapy in solid tumors. HBM4003 is expected to overcome the efficacy and safety bottlenecks of existing molecules and become a core product in the field of tumor immunotherapy. HBM7008 HBM7008 is a bispecific antibody targeting tumor-related antigens B7H4 and 4-1BB. Since it relies heavily on tumor-related antigens as mediated and cross-linked with T-cell activation, it not only has remarkable efficacy in co-stimulating T cells and inhibiting tumor growth, but is also expected to improve safety. HBM7008 is one of the all-human bispecific antibodies developed based on our HBICE platform, and is currently the only clinical-stage bispecific antibody against these two targets in the world. Its unique tumor expression specificity and immunomodulatory activity are expected to produce better curative effects in PD-L1 negative patients or patients resistant to PD1/PD-L1 immunotherapy drugs. With its novel biological mechanism of action and dual antibody design, it is hoped to avoid the risk of hepatotoxicity observed by 4-1BB in other products. Committed to the discovery and development of differentiated antibody therapies in the fields of tumor immunity and autoimmune diseases, we have also explored and developed a number of projects, including novel and challenging monoclonal antibody projects, such as HBM1022 (CCR8), HBM1020 (B7H7/HLA2, also potentially the first of its kind for this target), HBM1007 (a CD73-targeting monoclonal antibody with a dual mechanism of action), and HBM1047 (a type) HBM9378 CD200R1 targeting monoclonal antibodies), and bispecific antibodies generated on the HBICE platform. These antibodies have novel designs and differentiated mechanisms of action, such as HBM7020 (bCmaxCD3), HBM9027 (PD-L1x CD40), HBM7022 (Cldn18.2xCD3), and HBM7004 (B7H4x4-1bb). Furthermore, based on Harbour Mice's platform advantages, we have explored more immuno-oncology treatment pathways, such as HBM9033 (an ADC targeting MSLN). Leading drug innovation and discovery engine HBM4003 and many other in-house projects were developed on our proprietary Harbour Mice platform. Our HarbourMice platform can produce classic double chain double light chain (H2L2) and heavy chain only (HCaB) monoclonal antibodies. The H2L2 platform can rapidly and on a large scale manufacture of typical double and double light immunoglobulin chain antibodies (H2L2) with modified whole-human variable regions to achieve endogenous affinity maturation and immune effect functions. The HCaB platform is a human-derived antibody platform that can manufacture different morphologies of “heavy chain only” antibodies (such as mRNA, nanoantibodies, bispecific or multi-specific antibodies, and CAR-T), and has good development feasibility. With the proprietary technical knowledge accumulated from the HCaB platform, we have independently developed the HBICE platform, which focuses on generating differentiated bispecific antibodies based on HCaB immune cell connectors (which are expected to achieve tumor elimination effects that cannot be achieved with combination therapy). Combined with our monoclonal B cell screening platform, our high-efficiency antibody discovery engine has effectively fueled the company's innovation and sustainable growth. Based on the unique leading edge of the technology platform and the technical advantages of the team, we established Nona Biosciences in 2022 to better empower industry innovation and provide our partners with assistance throughout the iTOITM (idea to IND declaration) process. Nona Biosciences is an international biotechnology company that uses the technical advantages of the Harbour Mice platform and experienced therapeutic antibody discovery teams to provide overall solutions to partners from research institutes, biotech startups, and global biomedical giants around the world. One-stop antibody development services range from antigen preparation, animal immunity, single B cell screening, to lead antibody generation, engineering modification, developability assessment and related pharmacological evaluation. Commercial cooperation to maximize the value of the platform We have global rights to use and develop platinum antibody platforms, enabling us to maximize the value of our platforms to address unmet global healthcare needs. We are expanding our business partnerships with leading academic institutions around the world and selecting industry partners focused on innovation and efficiency. Our Harbour Therapeutics' business partnership model is not limited to pure technology licensing, but also includes incubating co-development and joint ventures with academic institutions or other leading innovators in the industry on the next generation of innovative therapeutics. The platform has been recognized by more than 50 industry and academic partners. Based on our good track record of cooperation, we believe that the Heplatinum Antibody Platform will have the potential to generate revenue and expand the scope of our R&D work. In addition to collaborating through platform-based molecules and product pipelines, we are also focusing on more original and innovative project collaborations that are still in the early stages of development. By integrating the advantages of the industry-leading Harbour Mice platform and the resources of our experienced therapeutic antibody development team, Nona Biosciences uses a flexible business model to provide a one-stop solution from I to ITM for therapeutic antibody discovery, engineering transformation and development. We believe Nona Biosciences will show us a new path to expand our network of partnerships and maximize the value of our platform.